focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.50
Ask: 4.50
Change: 0.49 (13.96%)
Spread: 1.00 (28.571%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Totally slides again; Proteome warns on earnings

Thu, 30th Nov 2023 11:04

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Ashtead Technology Holdings PLC, up 20% at 582.00 pence, 12-month range 281.00p-594.00p. The subsea equipment rental, serving the offshore energy sector, says it now expects 2023 results to be "comfortably ahead of its previous expectations". It also announces a GBP53.5 million deal to acquire ACE Winches, from that firm's founders Alfie and Valerie Cheyne. ACE offers lifting, pulling and deployment services, and will sit nicely with "Ashtead Technology's existing equipment and services portfolio", it says.

----------

AIM - LOSERS

----------

Proteome Sciences PLC, down 25% at 4.54p, 12-month range 3.15p-8.79p. The protein-focused drug development services provider cuts its revenue outlook for 2023 amid delays to projects. It expects its top line to shrink from 2022's GBP7.8 million. "As reported by many other life science technology providers, the company has experienced delays to projects, many of which have been postponed to 2024. The healthcare industry has faced a very challenging market environment this year, especially in the second half of the year," Proteome Sciences explains. Proteome adds that reduced revenue combined with its commitment to invest in a US lab, means its now expects to post a net loss for 2023. In 2022, the company posted a profit after tax of GBP1.3 million. Proteome says it expects its US laboratory to be operational in the coming weeks and is lining up first customer projects for this laboratory.

----------

Totally PLC, down 16% at 4.85p, 12-month range 4.80p-38.00p. A poor week for the stock continues and it looks likely to suffer a fourth-successive share price decline. On Tuesday, the healthcare services provider in UK and Ireland reported that it swung to a pretax loss of GBP1.9 million in the first half ended September 30, from a profit of GBP1.0 million the year prior. Revenue fell 21% to GBP55.8 million during the period, from GBP70.3 million a year ago, Totally said. The firm blamed a "crisis" faced by the UK NHS for the lower revenue, given the loss of its North West London contracts. Shares have fallen 48% so far this week and it hit this 12-month low on Thursday.

----------

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
25 Sep 2014 09:58

Proteome Unit Wins Alzheimer's Diagnostics Contract With Genting TauRx

Read more
8 Jul 2014 17:00

DIRECTOR DEALINGS: Proteome Sciences Non-Executive Buys Shares

Read more
8 Jul 2014 11:22

REPEAT: UK MIDDAY BRIEFING: M&S Online Sales Slump On Website Move

Read more
8 Jul 2014 11:19

UK MIDDAY BRIEFING: M&S Sales Slump On Website Move

Read more
8 Jul 2014 10:42

UK WINNERS & LOSERS: Airline Stocks Nosedive On Air France-KLM Warning

Read more
8 Jul 2014 08:45

UPDATE 1-Study paves way for simple blood test to predict Alzheimer's

* Fatal brain-wasting disease has no effective treatments * Experts say drug failures may be due to late trials * Predictive test could find people before disease sets in * Shares in Proteome Sciences, involved in work, jump 12 pct (Adds Proteome Sciences stock move) By

Read more
8 Jul 2014 08:26

Proteome Sciences Publishes Study For Alzheimer's Blood Test

Read more
29 May 2014 10:22

Proteome Sciences Confident For Revenue Growth As Loss Narrows

LONDON (Alliance News) - Proteome Sciences PLC Thursday expressed confidence for continued fast revenue growth for the "forseeable future", as it posted a narrowed pretax loss for 2013, driven by strong sales of its Tandem Mass Tag reagents and growth in its biomarker assays. Proteome is en

Read more
27 Mar 2014 14:08

Proteome Says Study Using SysQuant Technology Demonstrates Its Potential

LONDON (Alliance News) - Proteome Sciences PLC said Thursday that a study using its SysQuant technology to address pancreatic cancer published in medical journal PLOS ONE demonstrated the potential of proteomics to improve the way that bespoke treatments can be made to match patients. Prote

Read more
28 Feb 2014 16:18

XP Power board members reduce holdings

XP Power's Chairman, Larry Tracey, on Thursday sold 75,000 shares in the power supply solutions manufacturer. Tracey, who has held his current role since April 2002, disposed of the shares at 1,755p a time, generating a total of £1.3m. Fellow board member James Peters, a Non-Executive Director, t

Read more
24 Feb 2014 10:48

Proteome Sciences To Raise GBP5 Million In Share Placing

LONDON (Alliance News) - Proteome Sciences PLC said Monday it has placed 17.9 million new shares on the market to raise GBP5 million before expenses, with new and existing investors, which it will use for additional working capital. The protein biomarker company said the shares were placed

Read more
7 Feb 2014 10:06

Proteome edges ahead after flagging rise in revenue

Biotech group Proteome Sciences edged ahead after it revealed it expects revenue for 2013 to show "a significant increase" over 2012 thanks to strong performance across its core activities. The firm is an expert in biomarkers, or biological markers, that can help predict the likelihood of cancer r

Read more
7 Feb 2014 09:08

Proteome Sciences Says 2013 Revenues To Be Significantly Up

LONDON (Alliance News) - Shares in Proteome Sciences PLC rose in early trading Friday, after the protein biomarker company said revenue for 2013 will be significantly higher than the prior year, driven by a strong performance from all its core activities. Proteome is engaged in research an

Read more
4 Dec 2013 10:39

Proteome Sciences unveils sales delays, shares fall

Biotechnology group Proteome Sciences is facing sales delays that will push revenue from some deals into next year, hitting its shares. Proteome, which carries out research into protein and peptide biomarkers to treat neurological conditions and other illnesses such as cancer, said the timing and r

Read more
20 Nov 2013 10:55

Proteome Sciences Says Study Using Its Workflows Shows New Protein Biomarkers For Liver Cancer

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.